Genetix Biotherapeutics Inc., the commercial leader in genetic medicine for rare disease with a focus on hematology, today announced that the Company will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, at 2:30 p.m. GMT.

David Meek, Chief Executive Officer of Genetix, will provide the first public update on the Company's rapid transformation into a scalable, profitable commercial enterprise, highlighting continued commercial momentum, growth trajectory, and strategic priorities.

About Genetix Biotherapeutics Inc.
Genetix Biotherapeutics Inc. is a privately held, commercial-stage biotechnology company pioneering the field of genetic medicine. With more than 30 years of experience, Genetix is dedicated to delivering transformative, one-time treatments for patients with rare disease, with a focus on hematology. The company has three FDA-approved gene addition cell therapies for sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy, designed to treat the underlying cause of disease with a single dose and deliver durable clinical benefit. Genetix is headquartered in Somerville, Massachusetts.

Website: www.genetixbiotx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110095503/en/